$6M bankrolls Enveric pipeline partnering, depression program [Green Market Report]
Wednesday, May 15, 2024 1 min read
Key Takeaway: Enveric Biosciences has announced a partnership with MindBio and is pursuing licensing contracts for its pipeline candidates. The company reported a net loss of $2.46 million for Q1 2024 but raised $4.5 million through equity issuances. Enveric is focusing on advancing its lead non-hallucinogenic asset.
Price reaction · baseline $141.642 (2024-05-15T17:34:00.000Z) · hit during market hours · 3 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+0.1%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric is advancing its pipeline with a new partnership.
The company is focusing on non-hallucinogenic assets.
Recent fundraising efforts have bolstered its financial position.
CONCERNS & RISKS
Enveric reported a net loss of $2.46 million for Q1 2024.
The company has limited cash reserves of $6.36 million.
Full Press Release Details
On the heels of its announced partnership with MindBio (CNSX: MBIO) this week, Enveric Biosciences (NASDAQ: ENVB) said that it is trying to nail down potential licensing contracts for more of its pipeline candidates, as the biotech company also advances a lead “non-hallucinogenic” asset, it said in an earnings release Wednesday. In the first quarter ending March 31, the clinical-stage biotech company reported a net loss of $2.46 million for the first quarter of 2024. Enveric had $6.36 million in cash remaining at the end of March after raising $4.5 million in the quarter from warrant and equity issuances, the company said.
Full Article >>
Frequently Asked Questions
What recent partnership did Enveric announce?
Enveric announced a partnership with MindBio this week.
What was Enveric's net loss for Q1 2024?
Enveric reported a net loss of $2.46 million for the first quarter of 2024.
How much cash did Enveric have at the end of March?
Enveric had $6.36 million in cash remaining at the end of March.
What type of assets is Enveric focusing on?
Enveric is focusing on advancing non-hallucinogenic assets.